Evercore ISI Group maintains Inspire Medical Systems at In-Line, lowers price target to $60 from $72
Evercore ISI Group maintained its In-Line rating for Inspire Medical Systems but reduced its price target to $60 from $72. This implies a 10.7% downside from the Nov 2 close of $67.21. Recent analyst price targets for the company range from $62 to $78.
How this was made

The 30-second read
Why it matters
The target reduction signals a bearish view, likely prompting short‑term sell pressure.
Market read
Analyst target cut may influence INSP's price action and sentiment in the medical‑device sector.
What to watch
Potential pipeline developments not reflected in the target change.
Background
Evercore ISI provides analyst coverage for Inspire Medical Systems, a Nasdaq‑listed medical device company.
Ticker impact
Evercore ISI lowered its price target for Inspire Medical Systems to $60 from $72.
likely pressure as investors price in the lower target
Target cut implies downside of ~10% from recent close, prompting sell pressure.
Market effects
May weigh on other sleep‑apnea device makers.
Limited to US biotech/medical device sector.
Minimal global impact.
Counterpoint
Target cut could be over‑reactive; upside if upcoming trial data beats expectations.
Key entities
- CompanyInspire Medical Systems
Developer of sleep‑apnea therapy devices, ticker INSP.
- AnalystEvercore ISI Group
Equity research firm that issued the price‑target downgrade.



